Immunovant reports widened Q3 net loss of $63.2M; cash $432.6M; batoclimab trials on track

Immunovant, Inc.

2023-Q3 EPS reported -$1.26

Net loss $63.2M ($0.49/share) vs $41.4M ($0.36) prior year; R&D spend rose to $42.3M.
Cash $432.6M expected to fund operations into second half of calendar 2025.
Phase 1 trial of IMVT-1402 to start early 2023; initial data expected mid-2023.
Phase 3 batoclimab in TED initiated; Phase 2b in CIDP started; topline results H1 2025 and H1 2024.
Batoclimab development for warm AIHA discontinued; indication reserved for IMVT-1402.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immunovant, Inc. reported fiscal nine months ended December 31, 2022 results: net income $151.5 million ($1.26 per common share), EPS ($1.26 per common share).

Period: fiscal nine months ended December 31, 2022
Net income: $151.5 million ($1.26 per common share)
EPS: ($1.26 per common share)
Result: reported results

Exact text from the filing

Net loss was $151.5 million ($1.26 per common share) for the nine months ended December 31, 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immunovant, Inc. reported fiscal third quarter ended December 31, 2022 results: net income $63.2 million ($0.49 per common share), EPS ($0.49 per common share).

Period: fiscal third quarter ended December 31, 2022
Net income: $63.2 million ($0.49 per common share)
EPS: ($0.49 per common share)
Result: reported results

Exact text from the filing

Net loss was $63.2 million ($0.49 per common share) for the three months ended December 31, 2022

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunovant, Inc. filing history →

Source: SEC EDGAR

accession 0001764013-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.